Inhibition of glycolysis by a novel EGFR/HER2 inhibitor KU004 suppresses the growth of HER2+ cancer (Q38770333)

6 September 2017

title

Inhibition of glycolysis by a novel EGFR/HER2 inhibitor KU004 suppresses the growth of HER2+ cancer (English)

1 reference

6 September 2017

Chongchong Tian

1

1 reference

6 September 2017

Ziqiao Yuan

2

1 reference

6 September 2017

Dengqiu Xu

3

1 reference

6 September 2017

Pingping Ding

4

1 reference

6 September 2017

Tao Wang

5

1 reference

6 September 2017

Luyong Zhang

6

1 reference

6 September 2017

Zhenzhou Jiang

7

1 reference

6 September 2017

language of work or name

English

0 references

publication date

19 May 2017

1 reference

Experimental Cell Research

6 September 2017

published in

1 reference

6 September 2017

volume

357

1 reference

6 September 2017

issue

2

1 reference

6 September 2017

page(s)

211-221

1 reference

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Acidic tumor microenvironment in human melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Regulation of cancer cell metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Why do cancers have high aerobic glycolysis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Hallmarks of Cancer: The Next Generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

The soluble but not mitochondrially bound hexokinase is a substrate for the ATP- and ubiquitin-dependent proteolytic system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Cooperation and competition in the evolution of ATP-producing pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

HER2 in prostate cancer--a viable target or innocent bystander?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

The role of HER2 in cancer therapy and targeted drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

On the Origin of Cancer Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Untangling the ErbB signalling network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2017.05.019

10.1016/J.YEXCR.2017.05.019

7 January 2021

Identifiers

DOI

1 reference

6 September 2017

1 reference